EA201300867A1 - ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ - Google Patents
ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВInfo
- Publication number
- EA201300867A1 EA201300867A1 EA201300867A EA201300867A EA201300867A1 EA 201300867 A1 EA201300867 A1 EA 201300867A1 EA 201300867 A EA201300867 A EA 201300867A EA 201300867 A EA201300867 A EA 201300867A EA 201300867 A1 EA201300867 A1 EA 201300867A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- kinase inhibitors
- mtor kinase
- virus agents
- modulators
- mtor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Данное изобретение относится к способам лечения или предотвращения вирусных инфекций с использованием модуляторов ферментов клетки-хозяина, имеющих отношение к mTOR. Это изобретение также относится к способам лечения и предотвращения вирусных инфекций с использованием модуляторов ферментов клетки-хозяина, имеющих отношение к mTOR, и модуляторов реакции несвернутых белков.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161436970P | 2011-01-27 | 2011-01-27 | |
PCT/US2012/023035 WO2012103524A2 (en) | 2011-01-27 | 2012-01-27 | Inhibitors of mtor kinasa as anti- viral agents |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201300867A1 true EA201300867A1 (ru) | 2014-03-31 |
Family
ID=46581443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201300867A EA201300867A1 (ru) | 2011-01-27 | 2012-01-27 | ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ |
Country Status (6)
Country | Link |
---|---|
US (1) | US20140206678A1 (ru) |
EP (1) | EP2667874A4 (ru) |
JP (1) | JP2014505076A (ru) |
CA (1) | CA2825825A1 (ru) |
EA (1) | EA201300867A1 (ru) |
WO (1) | WO2012103524A2 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9333219B2 (en) | 2012-08-03 | 2016-05-10 | Albert Einstein College Of Medicine, Inc. | Method to treat or prevent herpesvirus infections |
US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
MX2016009753A (es) | 2014-01-28 | 2017-07-07 | Buck Inst For Res On Aging | Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud. |
US11083725B2 (en) * | 2014-10-24 | 2021-08-10 | St. Jude Children's Research Hospital | Coordinated metabolic reprogramming in response to productive viral infections |
WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
BR112019010470A2 (pt) | 2016-11-23 | 2019-09-10 | Novartis Ag | métodos de realce de resposta imune com everolimo, dactolisib ou ambos |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
US20240033236A1 (en) * | 2020-10-13 | 2024-02-01 | The Board Of Trustees Of The University Of Illinois | Methods of treating herpes viral infection with 4-phenylbutyrate (pba) or a pharmaceutically acceptable salt thereof |
WO2022106579A1 (en) * | 2020-11-20 | 2022-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compounds for treating a disease associated with macrophage senescence |
CN114748482B (zh) * | 2022-04-29 | 2023-09-26 | 广东龙帆生物科技有限公司 | 一种pf-04691502在制备用于抗腺病毒感染的药物中的用途 |
CN114948971A (zh) * | 2022-04-29 | 2022-08-30 | 广东龙帆生物科技有限公司 | 一种Vistusertib在制备用于抗腺病毒感染的药物中的用途 |
CN114652728A (zh) * | 2022-04-29 | 2022-06-24 | 广东龙帆生物科技有限公司 | 一种Apitolisib在制备用于抗腺病毒感染的药物中的用途 |
CN114652727B (zh) * | 2022-04-29 | 2023-10-27 | 广东龙帆生物科技有限公司 | 一种wye-125132在制备用于抗腺病毒感染的药物中的用途 |
CN115381828B (zh) * | 2022-08-04 | 2023-04-28 | 武汉市金银潭医院(武汉市传染病医院) | Pilaralisib在制备抗肠道病毒71型药物中的应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
WO2002088124A2 (en) * | 2001-04-27 | 2002-11-07 | Smithkline Beecham Corporation | Pyrazolo'1,5-a!pyridine derivatives |
KR101402474B1 (ko) * | 2006-04-26 | 2014-06-19 | 제넨테크, 인크. | 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물 |
AR060631A1 (es) * | 2006-04-26 | 2008-07-02 | Piramed Ltd | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) |
KR101422301B1 (ko) * | 2006-04-26 | 2014-07-30 | 에프. 호프만-라 로슈 아게 | 약학적 화합물 |
CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
AU2007328872A1 (en) * | 2006-12-06 | 2008-06-12 | Japan Science And Technology Agency | Potentiation of cellular immunity using histone deacetylase (HDAC) inhibitors |
ZA200904531B (en) * | 2006-12-07 | 2010-09-29 | Hoffmann La Roche | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
CN101616672A (zh) * | 2007-02-20 | 2009-12-30 | 诺瓦提斯公司 | 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类 |
AU2008287542C1 (en) * | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
GEP20125589B (en) * | 2008-05-23 | 2012-07-25 | Wyeth Llc | TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS |
WO2010006072A2 (en) * | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
AU2009279661A1 (en) * | 2008-08-05 | 2010-02-11 | Emory University | Use of mTOR inhibitors to enhance T cell immune responses |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
JP5452617B2 (ja) * | 2009-01-08 | 2014-03-26 | キュリス,インコーポレイテッド | 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター |
CN101869568A (zh) * | 2009-04-27 | 2010-10-27 | 中国医学科学院基础医学研究所 | 细胞自噬(ⅱ型细胞凋亡)作用抑制剂的用途 |
CA2768851A1 (en) * | 2009-07-23 | 2011-01-27 | The Trustees Of Princeton University | Inhibitors of mtor kinase as anti-viral agents |
WO2011019498A1 (en) * | 2009-07-27 | 2011-02-17 | The Trustees Of Princeton University | Inhibition of glycerol-3-phosphate acyltransferase (gpat) and associated enzymes for treatment of viral infections |
EP2536411A4 (en) * | 2010-02-18 | 2013-08-07 | Univ Princeton | HEMMER OF THE METABOLISM OF LOW-CHAIN AND VERY LOW-FATTYED FATTY ACIDS AS AN ANTIVIRUS ACTIVE SUBSTANCES WITH A WIDE SPECTRUM |
-
2012
- 2012-01-27 US US13/982,331 patent/US20140206678A1/en not_active Abandoned
- 2012-01-27 JP JP2013551397A patent/JP2014505076A/ja active Pending
- 2012-01-27 EA EA201300867A patent/EA201300867A1/ru unknown
- 2012-01-27 WO PCT/US2012/023035 patent/WO2012103524A2/en active Application Filing
- 2012-01-27 EP EP12739403.9A patent/EP2667874A4/en not_active Withdrawn
- 2012-01-27 CA CA2825825A patent/CA2825825A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2825825A1 (en) | 2012-08-02 |
WO2012103524A2 (en) | 2012-08-02 |
JP2014505076A (ja) | 2014-02-27 |
EP2667874A2 (en) | 2013-12-04 |
EP2667874A4 (en) | 2014-07-30 |
US20140206678A1 (en) | 2014-07-24 |
WO2012103524A8 (en) | 2013-09-12 |
WO2012103524A3 (en) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201300867A1 (ru) | ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ | |
BR112013021134A2 (pt) | moduladores e métodos de uso | |
EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
BR112013005116A2 (pt) | moduladores e métodos de uso | |
BR112013004776A2 (pt) | moduladores de proteína notum e métodos de uso | |
BR112014030639A2 (pt) | inibidores macrocíclicos de vírus flaviviridae | |
BR112014030630A2 (pt) | inibidores macrocíclicos de vírus flaviviridae | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201390190A1 (ru) | Ингибиторы вируса гепатита с | |
BR112013014119A8 (pt) | Novos moduladores e métodos de uso | |
BR112014030649A2 (pt) | inibidores macrocíclicos da flaviviridae vírus | |
EA201391152A1 (ru) | Ингибиторы вируса гепатита с | |
EA201790882A1 (ru) | Способы и композиции для терапии рака печени | |
MA35660B1 (fr) | Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile | |
EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
EA201391274A1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA201490450A1 (ru) | Новые ингибиторы ферментов | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
EA201790309A1 (ru) | Антитела к fap, способы их получения и применения | |
EA201391389A1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
AU2012249274A8 (en) | Neutralizing antibodies to Nipah and Hendra virus | |
EA201490627A1 (ru) | Соединения для улучшенной вирусной трансдукции |